Advanced search
Publication Cover
Future Oncology Volume 19, 2023 - Issue 9
Submit an article Journal homepage
6,684
Views
0
CrossRef citations to date
0
Altmetric
Clinical Trial Protocol

Brightline-1: phase II/III trial of the MDM2–p53 antagonist BI 907828 versus doxorubicin in patients with advanced DDLPS

Patrick Schöffski1 Department of General Medical Oncology, University Hospitals Leuven, Leuven Cancer Institute, & Department of Oncology, KU Leuven,Laboratory of Experimental Oncology, Leuven, BelgiumCorrespondence[email protected]
View further author information
,
Mehdi Lahmar2 Boehringer Ingelheim International GmbH, Ingelheim am Rhein, GermanyORCID Iconhttps://orcid.org/0009-0008-3022-8934View further author information
ORCID Icon,
Anthony Lucarelli3 Boehringer Ingelheim Pharmaceuticals Inc, Ridgefield, CT, USAView further author information
&
Robert G Maki4 Abramson Cancer Center, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA;5 Memorial Sloan Kettering Cancer Center, New York, NY, USAView further author information
Pages 621-629 | Received 22 Dec 2022, Accepted 01 Mar 2023, Published online: 29 Mar 2023

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.